BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22553996)

  • 1. Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations.
    Tangnararatchakit K; Tirapanich W; Anurathapan U; Tapaneya-Olarn W; Pakakasama S; Jootar S; Slavin S; Hongeng S
    Pediatr Transplant; 2012 Dec; 16(8):E342-7. PubMed ID: 22553996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
    Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
    Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance and chimerism after renal and hematopoietic-cell transplantation.
    Scandling JD; Busque S; Dejbakhsh-Jones S; Benike C; Millan MT; Shizuru JA; Hoppe RT; Lowsky R; Engleman EG; Strober S
    N Engl J Med; 2008 Jan; 358(4):362-8. PubMed ID: 18216356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic cell transplantation for the induction of allo- and xenotolerance.
    Sykes M
    Clin Transplant; 1996 Aug; 10(4):357-63. PubMed ID: 8884109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
    Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
    Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
    Mohamedbhai SG; Edwards N; Morris EC; Mackinnon S; Thomson KJ; Peggs KS
    Br J Haematol; 2012 Feb; 156(4):516-22. PubMed ID: 22171699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts.
    Prigozhina T; Slavin S
    Springer Semin Immunopathol; 2004 Nov; 26(1-2):169-85. PubMed ID: 15368079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed chimerism achieved by a nonlethal conditioning regimen induces donor-specific tolerance to lung allografts.
    Li S; Salgar SK; Kurimoto Y; Yousem S; Pham SM
    J Surg Res; 2008 May; 146(2):289-97. PubMed ID: 18314139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
    Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H
    Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
    Am J Hematol; ; . PubMed ID: 23450467
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.